Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB:CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good Manufacturing Practices (GMP) facility in January 2023.
經過成功的商業化生產試驗，生命科學生物科技公司Core One Labs Inc.(OTCQB：CLABF)該公司將於2023年1月在一家良好製造規範(GMP)設施開始臨床級別裸蓋菇素的商業生產。
In addition to psilocybin, the company intends to advance market production of its other Active Pharmaceutical Ingredient (API) psychedelic compounds towards eventually manufacturing and supplying them to licensed medical clinics and professionals, researchers and treatment development companies across Canada and other countries as well.
除了裸蓋菇素外，該公司還打算推進其其他活性藥物成分(API)迷幻化合物的市場生產，最終生產並供應給加拿大和其他國家的特許醫療診所和專業人員、研究人員和治療開發公司。
CEO Joel Shacker explained that the company is on course with the initial phase of testing its commercial capabilities for high-grade psilocybin.
首席執行官喬爾·沙克解釋說，該公司正在進行高級裸蓋菇素商業能力的初步測試。
"We anticipate positive results regarding Core One's commercial capabilities and quickly moving towards commercialization of our products; a milestone we anticipated will attract potential investors and please our current shareholders," Shacker stated.
沙克說：“我們預計Core One的商業能力將取得積極成果，並迅速將我們的產品商業化；我們預計這一裡程碑將吸引潛在投資者，並取悅我們現有的股東。”
Core One has developed and filed a patent for a novel psilocybin production system using engineered bacteria through its subsidiary company Vocan Biotechnologies. The company already holds four provisional patents for the development of psychedelic-based pharmaceutical formulations that target neurological and mental health disorders under its subsidiary Akome Biotech as well as three provisional patents for additional synthetic technologies for psilocybin and psilocin production methods under subsidiary Awakened Biosciences.
Core One通過其子公司Vocan BioTechnologies開發並申請了一項使用工程菌生產裸蓋菇素的新型系統的專利。該公司已經持有其子公司Akome Biotech旗下針對神經和精神健康障礙的迷幻劑藥物配方開發的四項臨時專利，以及子公司Awaded Biosciences旗下的裸蓋菇素和裸蓋菇素生產方法的額外合成技術的三項臨時專利。
Photo courtesy of Susie Hedberg and only_kim on Shutterstock.
照片由Susie Hedberg和Only_Kim在Shutterstock上提供。